Acadia Pharmaceuticals Inc
remlifanserin
Alzheimer’s disease psychosis
Countdown
55days
Phase 2 readout · Aug 31, 2026
What's at stake
Phase 2 trial results for remlifanserin in Alzheimer’s disease psychosis are due Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Phase 2 topline results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026 timeframe.”